Investment Insider: Pharmaceutical industry's best years lie ahead
I have heard many experts say that the best days of the pharmaceutical sector are behind it.
Drug developers are finding it harder to come up with new medicines – it is not easy to find a new statin or cholesterol-buster to compete with existing medications. Consequently, companies are forced to go to greater lengths to find new treatments as patents expire and me-too drugs appear.
That said, big pharmas such as GlaxoSmithKline boast a bulging pipeline of drugs in late-stage development. Many of these show promise and GSK expects a slew of drugs to gain regulatory approval in the next two years.
But for now, it has been a case of managing costs and generating cash from existing products. It is also keeping shareholders sweet by hiking its dividends. A prospective dividend yield of 5 per cent is welcome when stock markets are volatile. At 1,435p the shares are valued at around 11 times earnings, which is not too demanding.
AstraZeneca is going through similar patent-expiry pains. In the first quarter, revenues fell 11 per cent after it lost exclusivity on key brands. In fact, the fall for the year is likely to be in the mid-teens and the chief executive is to retire early. The shares are valued at eight times earnings which reflects the pessimism over future profits. But, there are no indications it intends to cut its dividend.
For investors with an eye on growth, Shire's business is founded on a strategy of buying young drugs from small biotechnology outfits and developing them. This has worked well with profits more than trebling in four years. The company does pay a small dividend, but rather than ratchet up its payout, Shire prefers to plough most of its earnings back into the business.
Hikma is another highly-rated growth company. It began as a one-product outfit with a bacterial infection-fighting drug. Today, it is a £1.3bn business that has doubled its sales and profits in four years . It is a good example of a Garp – Growth At a Reasonable Price – share, with a price/earnings to growth (PEG) ratio of 0.5. Ideally, you want a PEG ratio of less than one.
David Kuo is director financial website fool.co.uk
The best - and worst - investments in 2013
The death of the pension: how equity release can fund your retirement
How to start your own internet business
Julian Knight: We are seeing the dying days of the golden pension
Accident claims are shaken up: Insurers expect premiums to be held down by a new ruling. Ian Gregory reports
- 1 Pope Francis: Being an atheist is alright as long as you do good
- 2 What, let gays get married? We must be bonkers
- 3 'Something passed underneath us, quite close': Airbus A320 has close encounter with UFO
- 4 Lord of the Sings: Sir Christopher Lee, 91, to release heavy metal album
- 5 Two bailed after arrest over Woolwich attack Twitter comments
BMF is the UK’s biggest and best loved outdoor fitness classes
Find out what The Independent's resident travel expert has to say about one of the most beautiful small cities in the world
Nook is donating eReaders to volunteers at high-need schools and participating in exclusive events throughout the campaign.
Get the latest on The Evening Standard's campaign to get London's children reading.
Win anything from gadgets to five-star holidays on our competitions and offers page.
Day In a Page
A modern home of almost 1,000sq ft is close to Stoke Newington's high street. £499,950
A five-bedroom bungalow in Hoveton with riverside garden and mooring dock, £550,000
A refurbished one-bedroom flat with south-facing reception and high ceilings. £579,950
A four-bedroom Grade II-listed house in Nazeing with large gardens. £550,000
A modern four-bedroom house in a converted stable within walking distance to Peckham Rye. £695,000
Three-bedroom house in a quiet residential area within close distance to Battersea Park. £450,000
A three-bedroom cottage within commuting distance of London, Norwich and Cambridge. £250,000
A two-bedroom cottage with a sun room and gardens in South Chard. £350,000.
A three-bedroom semi-detached house with original features including fireplaces and wooden flooring. £399,950
A modern two-bedroom flat split across two floors and close to several public transport links. £595,000
A one-bedroom flat with an open-plan reception/kitchen and private balcony. £315,000.
A bright two-bedroom garden flat between South Acton and Chiswick Park. £499,950.
A listed four-bedroom farmhouse with stables, set in four acres. £500,000.
A three-storey family home with four bedrooms and an extended kitchen/diner. £995,000.
A three-bedroom Hamstone cottage in the rolling Somerset countryside. £430,000.
A luxury one-bedroom apartment on the first floor of a converted Victorian house. £425,000.